2Baselga J. The EGFR as a target for anticancer therapy-focus on cetuximab[J]. EurJ Cancer, 2001, 37 (Suppl 4): 16.
3Merlano M, Occelli M. Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck. Ther Clin Risk Manag, 2007, 3(5) : 871.
4Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody[J]. Drugs Today (Barc), 2005, 41: 107.
5Doody J F, Wang Y, Patel S N, et al. Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers [ J ]. Mol Cancer Ther, 2007, 6 (10) : 2642.
6Saltz L B, Meropol N J, Loehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor[J ]. J Clin Oncol, 2004, 22 (7): 1201.
8Vallb-hmer D, Zhang W, Gordon M, et al. Molecular determinants of cetuximab efficacy [J ]. J Clin Oncol, 2005, 23 (15) : 3536.
9Robertson JF,Osborne CK,Howell A,et al.Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women:a prospective combined analysis of two multicenter trials[J].Cancer,2003,98 (2):229-238
10Mauriac L,Pippen JE,Quaresma Albano J,et al.Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases:combined results from two multicentre trials[J].European Journal of Cancer,2003,39(9):1228-1233
6Romond E H, Perez E A, Bryant J, et al. Tras tuzum ab plus adjuvant chemotherapy for oper- able HER2 -positive breast cancer [ J ]. N Engl J Med,2006,353(16) :1 673- 1 684.
7Sánchez- Mufioz A,Pérez Ruiz E,Jiménez B,etal. Targeted thera- py of metastatic breast cancer [J]. Clin Transl Oncol, 2009, 11 (10): 643-650.
8Piccart - Gebhart MJ, Procter M, Leylomd - Jone B, et al. Trastuz - umah after adjuvant chemotherapy in HER - 2 - positive breast cancer[J]. N Engl J,2005,353(16) :1660 - 1672.
